Skip to search formSkip to main contentSkip to account menu

Measurable Disease

Known as: Measurable Lesion 
A tumor that can be accurately measured in size. This information can be used to judge response to treatment.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Erlotinib versus carboplatin/vinorelbine in elderly patients (age 70 or older) with advanced non-small cell lung carcinoma (NSCLC): A randomized phase II study of the German Thoracic Oncology Working…
7565 Background: Treatment of elderly patients remains a challenge. We compared the epidermal growth factor receptor (EGFR… 
2008
2008
Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium
5047 Background: Cediranib (AZD2171) is an oral highly potent, selective pan-VEGFR tyrosine kinase inhibitor expected to show… 
2008
2008
Feasibility and tolerability of the addition of erlotinib to 3D thoracic radiotherapy (RT) in patients (p) with unresectable NSCLC: A prospective randomized phase II study
7563 Background: RT is the standard treatment for p with unresectable or locally advanced NSCLC. Considering the high frequency… 
2008
2008
Vinorelbine and capecitabine combination as first-line treatment in patients with metastatic breast cancer: Final results of a multicentric trial in Egypt
1125 Background: The efficacy of vinorelbine with capecitabine was shown to be more than just additive in vitro. Moreover… 
2005
2005
Monitoring circulating tumor cells (CTC) in non-measurable metastatic breast cancer (MBC)
503 Background: We have previously reported that the presence of 5 or more circulating tumor cells (CTCs) in 7.5 mL of blood from… 
2004
2004
First-line single agent of gefitinib in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II study
7059 Background: Gefitinib is active for recurrent NSCLC after platinum-based chemotherapy (Fukuoka M, et al. J Clin Oncol 21… 
2000
2000
Declining CA-125 in an ovarian cancer patient with progression of measurable disease: a rational hypothesis for discordant results.
OBJECTIVES While a declining CA-125 has been demonstrated to be a useful indicator of response to chemotherapy in ovarian cancer… 
1987
1987
A Randomized Trial of Aminoglutethimide ± Estrogen Before Chemotherapy in Advanced Breast Cancer
Recent reports have suggested that the sensitivity to chemotherapy of endocrine-dependent breast cancer may be enhanced by… 
1983
1983
The use of different induction and maintenance chemotherapy regimens for the treatment of advanced yolk sac tumors.
Four children with yolk sac tumor were treated with an aggressive combination chemotherapy program. Three children had presacral… 
1979
1979
Phase II-III chemotherapy studies in advanced gastric cancer. Eastern Cooperative Oncology Group.
In this study, 139 eligible and evaluable patients with advanced gastric cancer, measurable disease, and no prior chemotherapy…